Extended Data Fig. 1: Change from baseline in HbA1c (a) and proportion of patients achieving HbA1c < 7.0% (b) at week 40 in the full analysis set.

LSMean changes from baseline in HbA1c were estimated using an ANCOVA with return-to-baseline multiple imputation for missing values at week 40 in patients who received at least 1 dose of study drug (5 mg, N = 230; 10 mg, N = 228; 15 mg, N = 229; insulin glargine, N = 220); statistical tests for 10 mg and 15 mg were two sided at a significance level of 0.025, statistical tests for 5 mg were two sided at a significance level of 0.05. Proportion of patients achieving HbA1c < 7.0% was estimated using logistic regression analysis with return-to-baseline multiple imputation for missing values at week 40 in patients who received at least 1 dose of study drug (5 mg, n = 230; 10 mg, n = 228; 15 mg, n = 229; insulin glargine, n = 220); all statistical tests were two sided at a significance level of 0.05. Error bars indicate SE. ANCOVA, analysis of covariance; HbA1c, glycated hemoglobin; LSMean, least-square mean; n, number of patients achieving target with missing value imputed by return-to-baseline multiple imputation; N, number of patients who were randomized and received at least 1 dose of study drug; SE, standard error.